When was Ashvattha Therapeutics founded?

Ashvattha Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is Ashvattha Therapeutics located?

Ashvattha Therapeutics is headquartered in Redwood City, United States.

Is Ashvattha Therapeutics a funded company?

Ashvattha Therapeutics is a funded company, having raised a total of $120M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 03, 2016.

When was the latest funding round of Ashvattha Therapeutics?

Ashvattha Therapeutics' latest funding was a $***** Series B round on Jan 14, 2025, with participation from 2 investors. Its primary sector is Nanotechnology. In United States, the Nanotechnology sector has seen $671M in funding in 2026 to date.

Where does Ashvattha Therapeutics rank among its competitors?

Ashvattha Therapeutics ranks 8th amongst 57 active competitors, of which 18 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Kala Pharmaceuticals, which secured $1.75M in Mar, 2026.

Who are the top competitors of Ashvattha Therapeutics?

Ashvattha Therapeutics' top competitors include Imbed Biosciences, NanoSyrinx and Tenpoint Therapeutics. Among them, Kala Pharmaceuticals secured the most recent funding round in March, 2026.

Ashvattha Therapeutics - 2026 Company Profile, Funding & Competitors

Ashvattha Therapeutics is a series B company based in Redwood City (United States), founded in 2015. It operates as a Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases. Ashvattha Therapeutics has raised $120M in funding from investors like Huadong Medicine, Natural Capital and Tribe Capital. The company has 57 active competitors, including 18 funded and 5 that have exited. Its top competitors include companies like Imbed Biosciences, NanoSyrinx and Tenpoint Therapeutics.

Company Details

Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases. The company uses hydroxyl dendrimer technology to selectively target inflamed tissue, and its pipeline highlights migaldendranib (MGB) as a key candidate for ophthalmology, neurology, and inflammatory diseases.

Website: avttx.com
Email ID: *****@avttx.com

Key Metrics

Founded Year

2015

Location

Redwood City, United States

Stage

Series B

Total Funding

$120M in 7 rounds

Latest Funding Round

Series B, Jan 14, 2025, $*****

Investors

Huadong Medicine & 12 more

Ranked

8^th among 57 active competitors

Similar Companies

Tenpoint Therapeutics & 34 more

View Ashvattha Therapeutics' full profile

Ashvattha Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ashvattha Therapeutics, Inc CIN: 474803849 , United States, Active		-	-	-

Ashvattha Therapeutics has raised a total funding of $120M over 7 rounds. Its first funding round was on Mar 03, 2016. Its latest funding round was a Series B round on Jan 14, 2025 for $*****. 2 investors participated in its latest round. Ashvattha Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Ashvattha Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 14, 2025	1813669	Series B	4396284	3824498	2289880	6127885
Apr 16, 2021	1227310	Series B	3813245	6301108	5117442	Plum Alley Investments & 2 more
May 31, 2019	5945041	Seed	6647526	8177577	4255922	2455205

Access funding benchmarks and valuations. Sign up today!

View details of Ashvattha Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ashvattha Therapeutics include Imbed Biosciences, NanoSyrinx and Tenpoint Therapeutics. Here is the list of Top 10 competitors of Ashvattha Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Imbed Biosciences 2010, Madison (United States), Series C	Provider of nanotech-based wound care products	$34.3M	Niterra, MassChallenge & 7 others	66/100
2nd	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
3rd	Tenpoint Therapeutics 2019, Warren (United States), Series B	Developer of engineered cell-based therapeutics to restore vision	$155M	EQT, Janus Henderson Investors & 20 others	61/100
4th	Kala Pharmaceuticals 2009, Waltham (United States), Public	Developer of ophthalmic treatments based on its mucosal penetrating product platform	$115M	Polaris Partners, Lux Capital & 17 others	59/100
5th	Character Biosciences 2019, San Francisco (United States), Series B	Developer of therapeutics for the treatment of age-related eye diseases	$120M	Innovation Endeavors, aMoon & 12 others	57/100
6th	Cour Pharma 2013, Chicago (United States), Series A	Developer of biotech nano-particles for immune diseases	$135M	Alpha Wave Global, Bristol-Myers Squibb & 6 others	57/100
7th	PulseSight 2008, Paris (France), Series B	Developer of non-viral minimally invasive gene therapies for retinal diseases	$54.2M	ND Capital, Boehringer Ingelheim Venture Fund ... & 10 others	56/100
8th	Ashvattha Therapeutics 2015, Redwood City (United States), Series B	Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases	$120M	Tribe Capital, Catalio Capital Management ... & 11 others	56/100
9th	Seabelife 2019, Roscoff (France), Seed	Developer of small-molecule drugs that simultaneously inhibit necroptosis and ferroptosis	$8.32M	iXLife Capital, Bpifrance & 9 others	53/100
10th	Humanetics Corporation 1988, Minneapolis (United States), Funding Raised	Clinical-stage biopharma company developing radiation modulators as therapeutics for solid cancers	-	Defense.gov, National Heart Lung and Blood Institute ... & 4 others	50/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Ashvattha Therapeutics's competitors? Click here to see the top ones

Ashvattha Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Ashvattha Therapeutics's sector:

Free

Nanotechnology - Sector Report

Edition: August, 2026 (71 Pages)

View all reports related to Ashvattha Therapeutics

Media has covered Ashvattha Therapeutics for a total of 4 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.